—
## What Harry Hollmann Saw
Harry T. Hollmann had a physician’s view of what Alice Ball’s work meant. He was a clinician, not a chemist; his understanding of the esterification chemistry was necessarily partial. What he had was clinical experience with the results. He had used the original oral and topical chaulmoogra preparations and seen their limitations. He had brought the problem to Ball because those limitations were real and consequential for his patients.
After Ball’s death, he had continued to use the injectable preparation she had developed — the production scaled up by Dean’s laboratory — in his clinical work at the Leprosy Investigation Station. He had watched patients respond to it in ways they had not responded to previous treatments. He had accumulated the clinical observations that allowed him to document, in his 1922 paper, the outcomes achieved with the Ball Method preparation.
His insistence in 1922 that Dean’s subsequent work represented no improvement on Ball’s original technique was a clinician’s judgment: the product he was receiving from Dean’s laboratory produced the same clinical outcomes as the product that had come from Ball’s original protocol. If the product performed identically, the protocol had not been meaningfully changed. Hollmann had the clinical experience to make that comparison.
What drove him to publish the 1922 paper — to go into print explicitly naming Ball and challenging Dean’s implicit priority claim — is not documented in ways that reveal his private reasoning. What is documented is that he did it, and that he did it with precision, naming Ball by name, calling the method the “Ball Method,” and directly contradicting Dean’s framing.
